Identification of G2/M targets for the MAP kinase pathway by functional proteomics
- PMID: 16858730
- DOI: 10.1002/pmic.200600365
Identification of G2/M targets for the MAP kinase pathway by functional proteomics
Abstract
Although the importance of the extracellular signal-regulated kinase (ERK) pathway in regulating the transition from G1 to S has been extensively studied, its role during the G2/M transition is less well understood. Previous reports have shown that inhibition of the ERK pathway in mammalian cells delays entry as well as progression through mitosis, suggesting the existence of molecular targets of this pathway in M phase. In this report we employed 2-DE and MS to survey proteins and PTMs in the presence versus absence of MKK1/2 inhibitor. Targets of the ERK pathway in G2/M were identified as elongation factor 2 (EF2) and nuclear matrix protein, 55 kDa (Nmt55). Phosphorylation of each protein increased under conditions of ERK pathway inhibition, suggesting indirect control of these targets; regulation of EF2 was ascribed to phosphorylation and inactivation of upstream EF2 kinase, whereas regulation of Nmt55 was ascribed to a delay in normal mitotic phosphorylation and dephosphorylation. 2-DE Western blots probed using anti-phospho-Thr-Pro antibody demonstrated that the effect of ERK inhibition is not to delay the onset of phosphorylation controlled by cdc2 and other mitotic kinases, but rather to regulate a small subset of targets in M phase in a nonoverlapping manner with cdc2.
Similar articles
-
Cdc2-mediated inhibition of epidermal growth factor activation of the extracellular signal-regulated kinase pathway during mitosis.J Biol Chem. 2005 Jul 1;280(26):24524-31. doi: 10.1074/jbc.M414079200. Epub 2005 May 11. J Biol Chem. 2005. PMID: 15888452
-
EphA2 phosphorylation at Ser897 by the Cdk1/MEK/ERK/RSK pathway regulates M-phase progression via maintenance of cortical rigidity.FASEB J. 2019 Apr;33(4):5334-5349. doi: 10.1096/fj.201801519RR. Epub 2019 Jan 22. FASEB J. 2019. PMID: 30668924
-
The ERK-RSK1 activation by growth factors at G2 phase delays cell cycle progression and reduces mitotic aberrations.Cell Signal. 2008 Jul;20(7):1349-58. doi: 10.1016/j.cellsig.2008.03.008. Epub 2008 Mar 21. Cell Signal. 2008. PMID: 18450423
-
Phosphorylation of transcription factors and control of the cell cycle.Crit Rev Eukaryot Gene Expr. 1995;5(1):1-77. Crit Rev Eukaryot Gene Expr. 1995. PMID: 7549180 Review.
-
ERK implication in cell cycle regulation.Biochim Biophys Acta. 2007 Aug;1773(8):1299-310. doi: 10.1016/j.bbamcr.2006.11.010. Epub 2006 Nov 17. Biochim Biophys Acta. 2007. PMID: 17188374 Review.
Cited by
-
Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2.J Proteome Res. 2011 Nov 4;10(11):4887-901. doi: 10.1021/pr2008994. Epub 2011 Oct 13. J Proteome Res. 2011. PMID: 21936567 Free PMC article.
-
Transforming growth factor-β activates c-Myc to promote palatal growth.J Cell Biochem. 2012 Oct;113(10):3069-85. doi: 10.1002/jcb.24184. J Cell Biochem. 2012. PMID: 22573578 Free PMC article.
-
NONO and tumorigenesis: More than splicing.J Cell Mol Med. 2020 Apr;24(8):4368-4376. doi: 10.1111/jcmm.15141. Epub 2020 Mar 13. J Cell Mol Med. 2020. PMID: 32168434 Free PMC article. Review.
-
Signaling diversity enabled by Rap1-regulated plasma membrane ERK with distinct temporal dynamics.Elife. 2020 May 26;9:e57410. doi: 10.7554/eLife.57410. Elife. 2020. PMID: 32452765 Free PMC article.
-
The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities.Front Oncol. 2022 Aug 10;12:982231. doi: 10.3389/fonc.2022.982231. eCollection 2022. Front Oncol. 2022. PMID: 36033439 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
